What changed with this FDA decision?

The FDA expanded Keytruda into adjuvant treatment for stage IB, II, and IIIA NSCLC after resection and platinum-based chemotherapy, giving Merck a new lung cancer label in early disease.

Who is affected by the approval?

Merck gains a broader Keytruda indication in the U.S., while oncology BD teams, investors, and analysts should monitor how the label affects competitive positioning in resectable NSCLC.

What should teams watch next?

Watch for follow-on clinical, regulatory, and commercial updates tied to Keytruda’s NSCLC lifecycle, including the October 2023 neoadjuvant approval and broader catalyst tracking in lung cancer.

Critical impact News 🇺🇸 FDA lung cancer FDA

Companies: Merck & Co.

Drugs: pembrolizumab, Keytruda

MSD MRK

Bd TeamsInvestorsAnalysts

FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label

100% citation coverage2 regulatory sources

The FDA approved pembrolizumab (Keytruda) for adjuvant treatment of stage IB, II, and IIIA non-small cell lung cancer after resection and platinum chemotherapy. For Merck and investors, the key readout is how this label expansion may shape lung cancer franchise momentum and future catalyst tracking.

Dr. Sarah Mitchell PharmD, RPh · Senior FDA Regulatory Correspondent

Reviewed by Dr. Sarah Chen Pharmaceutical Sciences Editor

Sunday, June 7, 2026 6 min read Updated Jun 7, 2026 Your watchlist

Intelligence Snapshot

Impact Score 92/100 Critical significance

Regulatory Impact 82/100 High agency relevance

Market Impact 82/100 High commercial pull

Clinical Relevance 77/100 High clinical weight

Evidence Strength 96/100 Critical source quality

Confidence Score 95/100 Critical certainty

Reading Time 6 min Executive read

Relevant for Pharma BD Investors Competitive Intelligence Regulatory Affairs Lung Cancer Teams

Executive Summary

Key Insights

A second Keytruda label expansion followed on October 16, 2023, when the FDA approved…

A second Keytruda label expansion followed on October 16, 2023, when the FDA approved pembrolizumab in combination with platinum-containing chemotherapy as neoadjuvant treatment for NSCLC.
Pembrolizumab is a PD-1 inhibitor, marking an immunotherapy option in the resectable lung…

Pembrolizumab is a PD-1 inhibitor, marking an immunotherapy option in the resectable lung cancer setting.
The adjuvant approval extends Merck's Keytruda franchise into early-stage disease, a…

The adjuvant approval extends Merck's Keytruda franchise into early-stage disease, a catalyst point for BD teams and investors tracking the company's oncology portfolio and label lifecycle.

Market Impact

Regulatory	high
Commercial	high
Competitive	medium
Investment	high

Drug pembrolizumab View profile

Drug Keytruda View profile

Patent US 12404497 — Uses and methods for oncolytic virus targeting o Patent intelligence

Patent US 12404328 — Multi-specific binding proteins and methods of u Patent intelligence

Patent US 12215135 — PDL2 compounds Patent intelligence

Patent US 12194081 — ARGINASE1 polypeptides Patent intelligence

Quick Answer

Key Questions

What is the specific indication for Keytruda's adjuvant approval?
How does the adjuvant approval relate to Keytruda's other NSCLC indications?
What should BD and investor teams track?
Is Keytruda the only PD-1 inhibitor with an adjuvant NSCLC approval?

Executive Scorecard

Heuristic scores · directional, not investment advice

Regulatory Readiness 82

Commercial Opportunity 82

Competitive Threat 60

Clinical Significance 74

Evidence Strength 96

Regulatory catalyst tracker

Track PDUFA dates, approval milestones, and label updates for pembrolizumab.

Jul 12, 2026 — PDUFA target
Priority Review — designation
Oncology — therapeutic area

Unlock full calendar →

Merck & Co. pipeline snapshot

One-screen view of active programs, phases, and recent catalysts from public sources.

View public profile →

Investor brief

Download a one-page summary of regulatory impact and competitive context.

Explore drug hub →

Contents15 sections

FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck's lung cancer label

IntelligenceRegulatory Impact

FDA decisions frame this story. Regulatory relevance is high for lung cancer, with pembrolizumab and Keytruda most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

On January 26, 2023, the FDA approved pembrolizumab (Keytruda) as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC following resection and platinum-based chemotherapy.
A second Keytruda label expansion followed on October 16, 2023, when the FDA approved pembrolizumab in combination with platinum-containing chemotherapy as neoadjuvant treatment for NSCLC.
Pembrolizumab is a PD-1 inhibitor, marking an immunotherapy option in the resectable lung cancer setting.
The adjuvant approval extends Merck's Keytruda franchise into early-stage disease, a catalyst point for BD teams and investors tracking the company's oncology portfolio and label lifecycle.

IntelligenceCompetitive Intelligence

Merck & Co. are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

The FDA approval and indication

On January 26, 2023, the FDA approved pembrolizumab (Keytruda; Merck) as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC following resection and platinum-based chemotherapy. The approval covers patients who have undergone surgical resection and completed platinum-containing chemotherapy, positioning Keytruda as a post-operative immunotherapy option in the early-stage lung cancer setting.

Pembrolizumab is a PD-1 inhibitor. The adjuvant label represents a new indication for Keytruda in the resectable early-stage NSCLC population.

IntelligenceMarket Signals

Commercial pull is high and investment relevance high for lung cancer. Expect implications for pricing, access, and launch sequencing.

Regulatory context and label expansion timeline

The January 2023 adjuvant approval marked a significant milestone for Keytruda in resectable lung cancer. The regulatory activity continued when on October 16, 2023, the FDA approved pembrolizumab in combination with platinum-containing chemotherapy as neoadjuvant treatment for NSCLC.

For BD teams and investors tracking Merck's oncology strategy, these sequential approvals represent catalyst events in the resectable lung cancer setting.

IntelligenceStrategic Takeaways

On January 26, 2023, the FDA approved pembrolizumab (Keytruda) as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC following resection and platinum-based chemotherapy . A second Keytruda label expansion followed on October 16, 2023, when the FDA approved pembrolizumab in combination with platinum-containing chemotherapy as neoadjuvant treatment for NSCLC. Pembrolizumab is a

What the approval means for Merck's franchise

The adjuvant label extension adds a new indication for Keytruda in early-stage NSCLC. The October 2023 neoadjuvant approval, which came nine months later, demonstrates ongoing regulatory activity for pembrolizumab in resectable disease.

IntelligenceEvidence Quality

Grounded in 2 regulatory sources.

Competitive context and treatment landscape

The evidence map does not specify competing approvals, trial outcomes, or the broader competitive adjuvant NSCLC approval landscape. BD teams evaluating immunotherapy options in early-stage lung cancer should consult FDA approval databases and clinical trial registries for a complete picture of available treatments in the adjuvant and neoadjuvant settings.

Drug Snapshot

Drug	pembrolizumab
Generic name	PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH
Drug class	Programmed Death Receptor-1 Blocking Antibody [EPC]
Manufacturer	Merck Sharp & Dohme LLC
Route	SUBCUTANEOUS
Indication	1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous N

Regulatory Summary

Approved indication: 1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous N
pembrolizumab is_class Programmed Death Receptor-1 Blocking Antibody [EPC]
Merck Sharp & Dohme LLC develops pembrolizumab

Trial Snapshot

Trial	Title	Status	Phase	Sponsor
NCT07353957	Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer	RECRUITING	PHASE2	Merus B.V.
NCT05232409	Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer	RECRUITING	PHASE1	Valley Health System
NCT05379972	Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers	COMPLETED	PHASE2	University of Colorado, Denver
NCT07198074	Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer	RECRUITING	PHASE3	National Cancer Institute (NCI)
NCT07276399	A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer	RECRUITING	PHASE3	Janssen Research & Development, LLC

Competitor Matrix

Company / Program	Indication	Active trials
National Cancer Institute (NCI)	lung cancer	3
Janssen Research & Development, LLC	lung cancer	2
Regina Elena Cancer Institute	lung cancer	1
National Heart, Lung, and Blood Institute (NHLBI)	lung cancer	1
Merus B.V.	lung cancer	1

Timeline

Recruiting trial NCT07353957 (PHASE2)
Recruiting trial NCT05232409 (PHASE1)
Recruiting trial NCT07198074 (PHASE3)
Recruiting trial NCT07276399 (PHASE3)
Recruiting trial NCT07353957 (PHASE2)

Frequently Asked Questions

What is the specific indication for Keytruda's adjuvant approval?

Keytruda is approved for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC following resection and platinum-based chemotherapy.

How does the adjuvant approval relate to Keytruda's other NSCLC indications?

The adjuvant indication extends Keytruda's use to the post-operative setting. The October 2023 neoadjuvant approval further extends pembrolizumab to the pre-operative setting in combination with platinum-containing chemotherapy.

What should BD and investor teams track?

BD and investor teams should monitor the adjuvant approval as a catalyst marker in Merck's lung cancer portfolio. The January 2023 adjuvant approval and the October 2023 neoadjuvant approval represent label expansions in the resectable NSCLC setting.

Is Keytruda the only PD-1 inhibitor with an adjuvant NSCLC approval?

The evidence provided does not specify the competitive adjuvant NSCLC approval landscape. BD teams should consult FDA approval databases and clinical trial registries for a complete picture of competing immunotherapy options in the adjuvant setting.

What to watch next

For BD and investor teams, the adjuvant approval marks a catalyst event in Merck's lung cancer franchise. The January 2023 adjuvant approval and the October 2023 neoadjuvant approval demonstrate regulatory activity in the resectable NSCLC space. Investors tracking Merck's oncology portfolio should monitor these label expansions as part of the company's overall lung cancer strategy.

Related profiles

pembrolizumab

Related coverage

Continue Exploring

Jump into the entities behind this story.

Drug pembrolizumab Explore → Drug Keytruda Explore → Company Merck & Co. Explore → Pipeline A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy Explore → Pipeline BNT327 20 mg ml, BNT327 50 mg ml, PEMBROLIZUMAB Explore → Pipeline Combination Treatment of PDS0101 and Pembrolizumab Explore → Pipeline KEYTRUDA 25 mg/mL concentrate for solution for infusion Explore → Regulator FDA Explore →

Ask AI About lung cancer

Grounded in NovaPharmaNews intelligence. Pick a prompt to start.

Evidence & Review

Sources analyzed: 2
Evidence strength: 96/100
Last verified: Jun 7, 2026
AI-assisted review: Yes
Editorial review: Dr. Sarah Chen

Critical source quality · grounded in cited primary and secondary sources.

This article follows our editorial standards. Report a correction via editorial contact.

pembrolizumab drug — FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label

About the Author

Dr. Mitchell has over 15 years of experience covering FDA drug approvals and regulatory policy.

FDA regulatorydrug approvalsoncology

Industry Reports & Whitepapers

Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…

Browse all whitepapers →